🏛️ Verified NIH Record • Updated 2026-07-14
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (NCT07096843)
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Climb Bio, Inc.
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Who can join: Review the eligibility criteria below.
Location: Climb Bio Investigative Site #110 — Denver, Colorado
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Climb Bio Investigative Site #110 — Denver, Colorado
- Climb Bio Investigative Site #105 — Orlando, Florida
- Climb Bio Investigative Site #108 — Atlanta, Georgia
- Climb Bio Investigative Site #106 — Indianapolis, Indiana
- Climb Bio Investigative Site #111 — Boston, Massachusetts
- Climb Bio Investigative Site #101 — Clifton Park, New York
- Climb Bio Investigative Site #104 — Sherman, Texas
- Climb Bio Investigative Site# 602 — Buenos Aires,
- Climb Bio Investigative Site# 603 — Buenos Aires,
- Climb Bio Investigative Site #601 — CABA,
- Climb Bio Investigative Site #604 — CABA,
- Climb Bio Investigative Site #606 — Santa Fe,
- Climb Bio Investigative Site #502 — Belo Horizonte,
- Climb Bio Investigative Site #505 — Minas Gerais,
- Climb Bio Investigative Site #506 — Pernambuco,
- Climb Bio Investigative Site #501 — Porto Alegre,
- Climb Bio Investigative Site #503 — São Paulo,
- Climb Bio Investigative Site #504 — São Paulo,
- Climb Bio Investigative Site #701 — Temuco, Araucania
- Climb Bio Investigative Site #703 — Valdivia, Los Ríos Region
- Climb Bio Investigative Site #702 — Santiago, Santiago Metropolitan
- Climb Bio Investigative Site #403 — Beijing, Changping District
- Climb Bio Investigative Site #401 — Beijing, Cheng District
- Climb Bio Investigative Site #408 — Shenzhen, Guangdong
- Climb Bio Investigative Site #402 — Wuxi, Jiangsu
📞 Contact the Study Coordinator
Phone: (866) 857-2596
Email: clinicaltrials@climbbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Membranous Nephropathy
- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Granada Hills, California
- A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — San Francisco, California
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Montgomery, Alabama
- Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Loma Linda, California
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Huntsville, Alabama
Explore by condition: All Primary Membranous Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.